EUVIMEDEUVIMED entdecken
FallberichtÜbersichtsarbeitOpen Access · CC BY 4.0

Concomitant ALK Fusion and TP53/EGFR Mutation Lead to Adverse Prognostic Outcome

Mingyuan Du iD, Cuiwei Liu, Leichong Chen iD, Zhenyu Li, Sijia Zhang, Rui Meng

The Clinical Respiratory Journal · 2024

DOI: 10.1111/crj.70041 ↗

Kurz gefasst

Fallbericht in der Zeitschrift The Clinical Respiratory Journal, 2024. Verfasst von Mingyuan Du und 5 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. Hauptthemen laut MEDLINE: Anaplastic Lymphoma Kinase, Carcinoma, Non-Small-Cell Lung, ErbB Receptors, Lung Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Hubei Province of China, Chinese Thoracic Oncology Group (CTONG).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lung cancer treatment has evolved at the molecular level. Detecting the presence of driver genes in lung cancer fundamentally alters the choice of therapeutic regimens and the outcome of this disease. ALK fusion mutation is one of the most important mutations in nonsmall cell lung cancer (NSCLC). Also, it often has other coexisting mutation types. TP53 is the most common coexisting mutation type, whereas the EGFR/ALK coexisting mutation type is extremely rare. There is still no definite conclusion about the impact of the multimutation and best treatment options for NSCLC patients with advanced multimutation. In this study, we report three cases of NSCLC with ALK fusion mutations as well as ALK combined with TP53 mutations and ALK combined with EGFR mutations. Combining cases from our oncology center and previous literature, we found that NSCLC patients with coexisting ALK fusion mutations and other mutations have poorer response to targeted therapy and poorer prognosis, and we also compared the efficacy rates of various types of coexisting mutations for different treatment regimens. Therefore, this review can help to evaluate the prognosis of NSCLC patients with coexisting mutations and the efficacy of targeted therapies and to find more favorable treatment options for patients with this type of coexisting mutations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anaplastic Lymphoma KinaseCarcinoma, Non-Small-Cell LungErbB ReceptorsLung NeoplasmsMutationTumor Suppressor Protein p53FemaleHumansMaleMiddle AgedPrognosis

Stichwörter der Autor:innen

ALK fusionEGFR mutationNSCLCTP53 mutationconcomitant

Substanzen

ALK protein, humanAnaplastic Lymphoma KinaseEGFR protein, humanErbB ReceptorsTP53 protein, humanTumor Suppressor Protein p53

Autor:innen und Institutionen

  • Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Hubei Key Laboratory of Precision Radiation Oncology, Wuhan, China.
  • Institute of Radiation Oncology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

ORCID-Profile: Mingyuan Du, Leichong Chen

Förderung

  • National Natural Science Foundation of China
  • Natural Science Foundation of Hubei Province of China
  • Chinese Thoracic Oncology Group (CTONG)
  • CSCO Cancer Research Fund

Zitieren

APA

Du, M., Liu, C., Chen, L., Li, Z., Zhang, S., & Meng, R. (2024). Concomitant ALK Fusion and TP53/EGFR Mutation Lead to Adverse Prognostic Outcome. The Clinical Respiratory Journal. https://doi.org/10.1111/crj.70041

Vancouver

Du M, Liu C, Chen L, Li Z, Zhang S, Meng R. Concomitant ALK Fusion and TP53/EGFR Mutation Lead to Adverse Prognostic Outcome. The Clinical Respiratory Journal. 2024. doi:10.1111/crj.70041

BibTeX
@article{Du2024,
  author = {Du, Mingyuan and Liu, Cuiwei and Chen, Leichong and Li, Zhenyu and Zhang, Sijia and Meng, Rui},
  title = {Concomitant ALK Fusion and TP53/EGFR Mutation Lead to Adverse Prognostic Outcome},
  journal = {The Clinical Respiratory Journal},
  year = {2024},
  doi = {10.1111/crj.70041}
}
Kostenlos starten →